
Developed novel chemistry that selectively delivers pharmaceuticals to a specific tissue
Mesentech has developed a bone-targeting prodrug MES1007 that avoids systemic exposure and side effects by specifically delivering drugs to the bone.
Boutique Venture Partners backs authentic founders who transform industries and create new ones in healthcare and life sciences.